洛铂与紫杉醇联合治疗晚期卵巢癌的临床观察.pdf

《洛铂与紫杉醇联合治疗晚期卵巢癌的临床观察.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、现代生物医学进展wwwashengwuyixue．comProgressinModernBiomedicineVok12NO28OCT．2012。5491·洛铂与紫杉醇联合治疗晚期卵巢癌的临床观察杨玉光李凌陈桂云梁欢吴瑾△(哈尔滨医科大学附属第三医院内七科黑龙江哈尔滨150040)摘要目的：观察洛铂与紫杉醇联合化疗治疗晚期卵巢癌的近期疗效及不良反应。方法：50例晚期卵巢癌(III期或Ⅳ期)患者，其中26例患者采用洛铂+紫杉醇静脉化疗，其中洛铂30medm，dl天，紫杉醇135~175mg／mdl天。24例患者采用顺铂+紫杉醇静脉化疗，其中顺铂25mg／m2d1．3天，

2、紫杉醇135~175mg／mdl天，2～4个疗程观察疗效。结果：26例洛铂组患者中，完全缓解7例，部分缓解8例，稳定9例，进展2例，有效率为57．7％。24例顺铂组患者中，完全缓解5例，部分缓解8例，稳定6例，进展5例，有效率为54．2％。主要毒副反应为骨髓抑制、骨骼酸痛、神经毒性和脱发。结论：洛铂联合紫杉醇治疗晚期卵巢癌疗效较好，毒副反应可以耐受。关键词：卵巢癌；洛铂；顺铂；紫杉醇中图分类号：R737．31文献标识码：A文章编号：1673—6273(2012)28-5491—03EficacyObservationofLobaplatinandPaclitaxelT

3、herapyinRecurrentAdvancedOvarianCarcinomaYANGYu-guang,LILing,CHENGui-yun,LIANGHuan,WUJin(TheThirdHospitalofHarbinMedicalUniversity,Heilongjiang,Harbin150040,China)ABSTRACTObjective：Toevaluatetheeffectsoflobaplatinandpaclitaxelontreatingrecurrentadvancedovariancarcinomaandtheiradve~ereac

4、tions．Methods：Atotalof50patients(III一1V)withrecurrentadvancedovariancarcinomawereenrolled，including26casesoflobaplatin+paclitaxeland24casesofcisplatin+paclitaxe1．Lobaplatingroup(1obaplatin十paclitaxe1)：lobaplatinatadoseof30mg／mintravenousinfusionond1．andpaclitaxelatadoseof135～175mg／m2int

5、ravenousinfusiononday1．Cisplatingroup(cisplatin+paclitaxe1)：cisplatinatadoseof24mg／m2intravenousinfusionondaylandpaclitaxelatadoseof135～175mg／m2intravenousinfusionond1．Theeficacywasevaluatedafter2～4cycles．Results：Lobaplatingroup：sevenpatientsachievedcompleteresponse(CR)。eightpa—tientsac

6、hievedpartialresponse(PR)，ninepatientsachievedstabledisease(SD)andtwopatientsachievedprogresseddisease(PD)．Theoverallresponserate(RR=CR“)was57．7％．Cisplatingroup：fivepatientsachievedCR，eightpatientsachievedPR，sixpatientsSDandfivepatientsachievedPD．Theoverallresponseratewas54．2％．Themajora

7、dverseefectswerebonemarrowdepression，arthralgia，neurotoxicityandalopecia．Conclusion：Combinedchemotherapyoflobaplatinandpaclitaxelhasagoodanti-tumoractivityandmanage—abletoxicityonrecurrentadvancedovariancarcinomapatients．Keywords：Ovariancarcinoma；Lobaplatin；Cisplatin；Paclitaxel